Market Overview:
The global performance enhancing drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing use of performance enhancing drugs by athletes, body builders, students and militaries across the globe. Additionally, factors such as rising awareness about the benefits of using performance enhancing drugs and increasing research and development activities for new products are also contributing to the growth of this market. On the basis of type, ergogenic aids accounted for a major share of the global performance enhancing drugs market in 2017. This can be attributed to their wide range of benefits such as improved athletic performance, increased strength and muscle mass, reduced fatigue levels and enhanced cognitive function. Nootropics are also gaining popularity owing to their ability to improve cognitive function and memory retention capacity among users. Geographically, North America held a dominant position in 2017 due its well-developed healthcare infrastructure coupled with high consumer awareness about various types of Performance Enhancing Drugs (PEDs).
Product Definition:
Performance enhancing drugs are substances that are taken to improve athletic or cognitive performance. The use of these drugs is banned in most sports, as they give an unfair advantage to the user.
by Type:
By type, it's usage.
The global what is by type, it's usage and growth factor in the performance enhancing drugs market size was valued at USD 4.6 billion in 2015. It is expected to grow with a CAGR of XX% over the forecast period (2016-2021).
Ergogenic Aids:
An ergogenic aids is any substance or device that helps the body to generate energy during physical activity. Some of the most common ergogenic aids are caffeine, creatine, beta-alanine, tyrosine and taurine. Ergogenic aids can be used by athletes as well as non-athletes in various sports activities such as cycling, weight lifting and football etc., to boost performance levels.
Application Insights:
The athletes segment held the largest market share in 2015 and is expected to continue its dominance over the forecast period. This can be attributed to increasing government funding for sportspersons as well as teams which promote performance enhancing drugs use among athletes. Moreover, a rise in number of professional sports players has also fueled this segment growth. The body builder¢â‚¬â„¢s application is expected to grow at a significant rate during the forecast period owing to increase in demand for muscle building supplements across the globe. Increasing fitness consciousness among working professionals along with growing spending power of consumers are some factors that may boost this segment growth soon.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. North America has a large number of fitness clubs and health centers, which increases awareness regarding performance enhancing drugs usage. Moreover, stringent regulations by the U.S Food and Drug Administration (FDA) for manufacturing and marketing these products are further anticipated to drive growth in this region.
Growth Factors:
- Increasing awareness about the benefits of performance enhancing drugs among athletes and sports enthusiasts.
- Growing demand for safe and effective performance enhancing drugs from professional athletes and bodybuilders.
- Rising popularity of muscle-building supplements among young people.
- Proliferation of online stores that sell performance enhancing drugs at competitive prices.
- increasing number of fitness clubs and gyms that offer training programs that include use of performance enhancing drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Performance Enhancing Drugs Market Research Report
By Type
by Type, Ergogenic Aids, Nootropic, by Products, Pills, Injections, Patches
By Application
Athletes, Body Builders, Students, Militaries
By Companies
Taj Pharmaceuticals, Balkan Pharmaceuticals, Bayer, AstraZeneca, Novo Nordisk, BrainAlert, Douglas Laboratories, Onnit Labs, Eli Lilly And Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Performance Enhancing Drugs Market Report Segments:
The global Performance Enhancing Drugs market is segmented on the basis of:
Types
by Type, Ergogenic Aids, Nootropic, by Products, Pills, Injections, Patches
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Athletes, Body Builders, Students, Militaries
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Taj Pharmaceuticals
- Balkan Pharmaceuticals
- Bayer
- AstraZeneca
- Novo Nordisk
- BrainAlert
- Douglas Laboratories
- Onnit Labs
- Eli Lilly And Company
Highlights of The Performance Enhancing Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- by Type
- Ergogenic Aids
- Nootropic
- by Products
- Pills
- Injections
- Patches
- By Application:
- Athletes
- Body Builders
- Students
- Militaries
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Performance Enhancing Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Performance enhancing drugs are any substances or techniques that a person uses to improve their performance in sports, work, or other activities. This can include things like steroids, human growth hormone (HGH), and caffeine.
Some of the major players in the performance enhancing drugs market are Taj Pharmaceuticals, Balkan Pharmaceuticals, Bayer, AstraZeneca, Novo Nordisk, BrainAlert, Douglas Laboratories, Onnit Labs, Eli Lilly And Company.
The performance enhancing drugs market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Performance Enhancing Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Performance Enhancing Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Performance Enhancing Drugs Market - Supply Chain
4.5. Global Performance Enhancing Drugs Market Forecast
4.5.1. Performance Enhancing Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Performance Enhancing Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Performance Enhancing Drugs Market Absolute $ Opportunity
5. Global Performance Enhancing Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Performance Enhancing Drugs Market Size and Volume Forecast by Type
5.3.1. by Type
5.3.2. Ergogenic Aids
5.3.3. Nootropic
5.3.4. by Products
5.3.5. Pills
5.3.6. Injections
5.3.7. Patches
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Performance Enhancing Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Performance Enhancing Drugs Market Size and Volume Forecast by Application
6.3.1. Athletes
6.3.2. Body Builders
6.3.3. Students
6.3.4. Militaries
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Performance Enhancing Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Performance Enhancing Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Performance Enhancing Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Performance Enhancing Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Performance Enhancing Drugs Demand Share Forecast, 2019-2029
9. North America Performance Enhancing Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Performance Enhancing Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Performance Enhancing Drugs Market Size and Volume Forecast by Application
9.4.1. Athletes
9.4.2. Body Builders
9.4.3. Students
9.4.4. Militaries
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Performance Enhancing Drugs Market Size and Volume Forecast by Type
9.7.1. by Type
9.7.2. Ergogenic Aids
9.7.3. Nootropic
9.7.4. by Products
9.7.5. Pills
9.7.6. Injections
9.7.7. Patches
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Performance Enhancing Drugs Demand Share Forecast, 2019-2029
10. Latin America Performance Enhancing Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Performance Enhancing Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Performance Enhancing Drugs Market Size and Volume Forecast by Application
10.4.1. Athletes
10.4.2. Body Builders
10.4.3. Students
10.4.4. Militaries
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Performance Enhancing Drugs Market Size and Volume Forecast by Type
10.7.1. by Type
10.7.2. Ergogenic Aids
10.7.3. Nootropic
10.7.4. by Products
10.7.5. Pills
10.7.6. Injections
10.7.7. Patches
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Performance Enhancing Drugs Demand Share Forecast, 2019-2029
11. Europe Performance Enhancing Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Performance Enhancing Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Performance Enhancing Drugs Market Size and Volume Forecast by Application
11.4.1. Athletes
11.4.2. Body Builders
11.4.3. Students
11.4.4. Militaries
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Performance Enhancing Drugs Market Size and Volume Forecast by Type
11.7.1. by Type
11.7.2. Ergogenic Aids
11.7.3. Nootropic
11.7.4. by Products
11.7.5. Pills
11.7.6. Injections
11.7.7. Patches
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Performance Enhancing Drugs Demand Share, 2019-2029
12. Asia Pacific Performance Enhancing Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Performance Enhancing Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Performance Enhancing Drugs Market Size and Volume Forecast by Application
12.4.1. Athletes
12.4.2. Body Builders
12.4.3. Students
12.4.4. Militaries
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Performance Enhancing Drugs Market Size and Volume Forecast by Type
12.7.1. by Type
12.7.2. Ergogenic Aids
12.7.3. Nootropic
12.7.4. by Products
12.7.5. Pills
12.7.6. Injections
12.7.7. Patches
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Performance Enhancing Drugs Demand Share, 2019-2029
13. Middle East & Africa Performance Enhancing Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Performance Enhancing Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Performance Enhancing Drugs Market Size and Volume Forecast by Application
13.4.1. Athletes
13.4.2. Body Builders
13.4.3. Students
13.4.4. Militaries
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Performance Enhancing Drugs Market Size and Volume Forecast by Type
13.7.1. by Type
13.7.2. Ergogenic Aids
13.7.3. Nootropic
13.7.4. by Products
13.7.5. Pills
13.7.6. Injections
13.7.7. Patches
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Performance Enhancing Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Performance Enhancing Drugs Market: Market Share Analysis
14.2. Performance Enhancing Drugs Distributors and Customers
14.3. Performance Enhancing Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Taj Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Balkan Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novo Nordisk
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BrainAlert
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Douglas Laboratories
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Onnit Labs
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Eli Lilly And Company
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
